巨子生物(02367)股价今日盘中出现大涨行情,大涨6.26%,引发市场关注。分析显示,这主要与两个利好消息有关:
首先,券商广发证券发布研究报告,维持巨子生物"买入"评级,预计公司未来3年归母净利润将持续增长,并给予公司合理价值55.72港元的目标价,对公司前景予以看好。
其次,巨子生物旗下针对颈纹的"注射用重组胶原蛋白填充剂"获得优先审批。这表明公司在医美领域的创新研发取得进展,为进一步开拓医美市场奠定了基础。据了解,巨子生物目前在医美领域的在研产品共有4款,产品矩阵丰富。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.